Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Stock Position Trimmed by Chatham Capital Group Inc.

Chatham Capital Group Inc. cut its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 30.2% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,873 shares of the medical equipment provider’s stock after selling 810 shares during the quarter. Chatham Capital Group Inc.’s holdings in Zimmer Biomet were worth $247,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the company. OLD Point Trust & Financial Services N A bought a new stake in shares of Zimmer Biomet during the 4th quarter worth about $26,000. Ables Iannone Moore & Associates Inc. bought a new stake in shares of Zimmer Biomet during the 4th quarter worth about $30,000. Naples Money Management LLC bought a new stake in shares of Zimmer Biomet during the 4th quarter worth about $35,000. Activest Wealth Management raised its position in shares of Zimmer Biomet by 410.4% during the 4th quarter. Activest Wealth Management now owns 342 shares of the medical equipment provider’s stock worth $42,000 after buying an additional 275 shares in the last quarter. Finally, Blue Trust Inc. grew its stake in shares of Zimmer Biomet by 48.4% in the 4th quarter. Blue Trust Inc. now owns 469 shares of the medical equipment provider’s stock worth $52,000 after purchasing an additional 153 shares during the last quarter. 88.89% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the stock. Needham & Company LLC reaffirmed a “hold” rating on shares of Zimmer Biomet in a research note on Thursday, May 30th. Citigroup lifted their price objective on shares of Zimmer Biomet from $134.00 to $140.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 3rd. Oppenheimer lifted their price objective on shares of Zimmer Biomet from $150.00 to $155.00 and gave the stock an “outperform” rating in a research note on Friday, May 3rd. Barclays lowered their price objective on shares of Zimmer Biomet from $130.00 to $125.00 and set an “underweight” rating on the stock in a research note on Friday, May 31st. Finally, Evercore ISI lifted their target price on shares of Zimmer Biomet from $125.00 to $130.00 and gave the stock an “in-line” rating in a research report on Thursday, April 4th. One analyst has rated the stock with a sell rating, nine have given a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $133.75.

Zimmer Biomet Trading Up 0.1 %

Shares of ZBH stock opened at $108.53 on Monday. Zimmer Biomet Holdings, Inc. has a 1 year low of $102.00 and a 1 year high of $147.50. The firm’s fifty day simple moving average is $115.29 and its 200 day simple moving average is $121.22. The firm has a market capitalization of $22.33 billion, a P/E ratio of 23.49, a price-to-earnings-growth ratio of 1.95 and a beta of 1.01. The company has a current ratio of 1.66, a quick ratio of 0.80 and a debt-to-equity ratio of 0.38.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Thursday, May 2nd. The medical equipment provider reported $1.94 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.87 by $0.07. The firm had revenue of $1.89 billion for the quarter, compared to analyst estimates of $1.87 billion. Zimmer Biomet had a net margin of 12.93% and a return on equity of 12.70%. The business’s revenue for the quarter was up 3.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.89 EPS. As a group, sell-side analysts predict that Zimmer Biomet Holdings, Inc. will post 8.1 EPS for the current year.

Zimmer Biomet Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, July 31st. Shareholders of record on Wednesday, June 26th will be issued a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 0.88%. The ex-dividend date is Wednesday, June 26th. Zimmer Biomet’s dividend payout ratio (DPR) is presently 20.78%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.